International Collaboration | Rogier Janssens, President of Merck China, Visits Shenzhen-Hong Kong Cell Valley

        On the morning of June 2, Rogier Janssens, President of Merck China, led a delegation to the Shenzhen-Hong Kong Cell Valley for a site visit and exchange. Professor Shi Yuanyuan, Chairman and General Manager of the Cell Valley Group, together with his core team, extended a warm welcome. The two sides held in-depth discussions on cutting-edge areas including cell and gene therapy, biomedical innovation and translation, and the integration of international resources, laying a solid foundation for future collaboration.

As a global pharmaceutical and technology company with over 350 years of history, Merck possesses world-leading technological expertise, a complete industrial chain, and extensive global resources in cell and gene therapy, bioprocess development, and innovative biomedicine. The company has long been committed to exploring China's local innovation market and continuously promoting the upgrading and development of the domestic life science industry.

During the exchange, Professor Shi Yuanyuan accompanied the delegation on a tour of the smart exhibition hall and product display area, showcasing the Cell Valley's core technologies, innovative products, and latest research achievements. He elaborated on the group's core competitive advantages, highlighting R&D breakthroughs and clinical progress in immune cells, stem cells, viral vectors, exosomes, and related fields. President Rogier Janssens spoke highly of the Cell Valley's technological strength and development potential, and introduced Merck's global footprint and technical expertise in the life science and healthcare sectors.

Professor Shi Yuanyuan remarked that the Cell Valley has always focused on the frontier of cell and gene therapy, deeply cultivating local industrial innovation and actively connecting with high-quality global industrial resources. The Cell Valley looks forward to strengthening communication and collaboration with world-class enterprises, leveraging the complementary resources and technological strengths of both sides to explore diverse models of synergy and jointly promote high-quality development of the biomedical industry in the Greater Bay Area.

 Profile of Merck Group

Merck KGaA, headquartered in Darmstadt, Germany, was founded in 1668. It is a leading global science and technology company and one of the oldest chemical and pharmaceutical companies in the world. With over 350 years of development, Merck has built a diversified business portfolio covering three core sectors: Life Science, Healthcare, and Electronics. From advanced gene-editing technologies and the discovery of unique approaches to treating challenging diseases, to enabling device intelligence, the company possesses strong R&D capabilities, an extensive manufacturing network, and a broad global market presence. Merck is dedicated to solving critical technological challenges across industries and delivering innovative products and solutions that serve global healthcare, semiconductor, biopharmaceutical, and other key sectors. In 2025, Merck generated total sales of €21.1 billion across 65 countries.